Výsledky vyhledávání - "Donald, Milligan"

Akademický článek

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Autor: Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock

Publikováno v: Haematologica, Vol 101, Iss 11 (2016)

Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have th

Externí odkaz: https://doaj.org/article/f772d011430040108f48560b445e89d7

Zobrazit plný text záznamu

Akademický článek

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia

Publikováno v: Haematologica, Vol 95, Iss 6 (2010)

Background Reduced intensity conditioning regimens permit the delivery of a potentially curative graft-versus-leukemia effect in older patients with acute myeloid leukemia. Although T-cell depletion is increasingly used to reduce the risk of graft-ve

Externí odkaz: https://doaj.org/article/9884d138637b4bb3ae5cc45c8ef54b74

Zobrazit plný text záznamu

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL

Autor: Alison Smith, Lucy McParland, Abraham M. Varghese, David Allsup, Peter Hillmen, Dena R. Howard, Anna Schuh, Andrew S Duncombe, Donald Milligan, Andy C. Rawstron, Anna Hockaday, Talha Munir, Roberta Longo, John O’Dwyer, Scott Marshall

Publikováno v: Leukemia. 31:2416-2425

ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33c048e2b0d00158e3d6961be7984ab
https://doi.org/10.1038/leu.2017.96

Zobrazit plný text záznamu

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

Autor: Nicki Panoskaltsis, Nigel H. Russell, Claire Hemmaway, Alan Kenneth Burnett, P Cahalin, Robert Kerrin Hills, Richard E. Clark, Donald Milligan, Asim Khwaja

Publikováno v: Leukemia. 29:1312-1319

The development of new treatments for older patients with acute myeloid leukaemia (AML) is an active area, but has met with limited success. Sapacitabine is a novel orally administered nucleoside analogue that has shown encouraging activity in unrand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254a1db38a0933f9b722090b3e79e49c
https://doi.org/10.1038/leu.2015.38

Zobrazit plný text záznamu

Primary care management of early stage chronic lymphocytic leukaemia is safe and effective

Autor: Jim Murray, Donald Milligan, Guy Pratt, Helen Parry, Tina McSkeane, S. Aung, Paul Moss, Peter Hazlewood, N. P. Mudondo, Sarah Damery

Publikováno v: QJM. 108:789-794

Background: Chronic lymphocytic leukaemia (CLL) is the commonest leukaemia in western society. Most patients are detected incidentally at an early stage and require ‘watch and wait’ follow-up. In the UK, management of Stage A0 CLL varies with som

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1cb09a5ae38793f9ad30a676fae520f
https://doi.org/10.1093/qjmed/hcv017

Zobrazit plný text záznamu

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Autor: Christopher Pocock, Donald Milligan, Stephan Oertel, Paul Moreton, Andrew R. Pettitt, Hazem A. Sayala, Abraham M. Varghese, George A Follows, John G. Gribben, David Oscier, Andy C. Rawstron, Daniel B. Kennedy, Dena Cohen, Amit Nathwani, Peter Hillmen, Claire Dearden

Publikováno v: Journal of Clinical Oncology. 32:1236-1241

Purpose Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For this population, chlorambucil monotherapy is an appropriate therapeutic option; how

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::959fdac1c1f4013b269daa45ee41a8e3
https://doi.org/10.1200/jco.2013.49.6547

Zobrazit plný text záznamu

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study

Publikováno v: American Journal of Hematology
American Journal of Hematology, Wiley, 2014, 89 (2), pp.174-180. ⟨10.1002/ajh.23610⟩
American Journal of Hematology, 2014, 89 (2), pp.174-180. ⟨10.1002/ajh.23610⟩
American Journal of Hematology, 89, 2, pp. 174-80
American Journal of Hematology, 89, 174-80
American Journal of Hematology, 89(2), 174-180. Wiley

Item does not contain fulltext In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efef45e841bc1bc3cf24126b8bbfa15
https://cris.maastrichtuniversity.nl/en/publications/68cf9d7c-184c-4331-a26d-9f3e6afe3b61

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání